Areas of Investigation
Our laboratory focuses on developing new and improved HIV vaccines. This work began in 1984 at Genentech and continues to this day. In 2009, the results of the RV144 clinical trial were published, which showed that immunization with a vaccine invented in our laboratory, AIDSVAX B/E, provided partial protection when combined with another vaccine named vCP1521.
The RV144 study, involving more than 16,000 Thai volunteers, was the first to show that vaccination could, in fact, prevent HIV infection. Development of a successful vaccine to protect against HIV infection would make a major impact on the worldwide spread of this deadly retroviral epidemic.